In the following review, we discuss four RCD pathways that may be activated to treat p53-mutant cancers, including E2F transcription factor 1 (E2F1)-dependent apoptosis, necroptosis, mitochondrial permeability transition driven necrosis, and ferroptosis. The gene discussed is TP53; the disease is cancer.